#793 Eckert & Ziegler forms joint venture for tumor irradiation devices in China

Eckert & Ziegler AG (ISIN DE0005659700), a global radioisotope specialist headquartered in Berlin, Germany, has formed a joint venture with Chinese TCL Healthcare Equipment (Shanghai) Co. Ltd.

#794 caresyntax and Insel Gruppe AG Launch Collaboration to Automate and Standardize Surgical Skills Assessment Using AI and Machine Learning

Will Enhance Surgical Skills and Enable a Higher Quality of Care for Both Patients and Caregivers BERLIN & BASEL, Switzerland–(BUSINESS WIRE)–caresyntax, a pioneering developer in surgical

#795 ProBioGen licenses GlymaxX® Technology to Bayer

ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the GlymaxX®

#796 ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology

ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR®

#797 Asahi Kasei Pharma contracts ProBioGen for the Advancement of their Biologics Pipeline

ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will

#798 Fine-tuning communication: How drugs and diseases influence signals between nerve cells

Nerve cells communicate with one another via signaling molecules. The rule is: the more of these molecules, the stronger the signal. Drugs and diseases influence these processes and can weaken or

#799 ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule

ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate. Founded in 2016, Lava

#800 Alrise announces acquisition of its ImSus® drug delivery technology by Ferring International Center S.A.

The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and

#801 Fine-tuning gene scissors: Computer model for adjusting CRISPR-Cas9 enables more precise cuts in the genome

The CRISPR-Cas9 gene-editing tool makes it possible to modify the genetic material of organisms. But CRISPR technology is not perfect. Frequently, these molecular “scissors” also make incisions in

#802 Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care

Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee (G-BA) with effect

#803 Recognise and control new variants of the deadly Ebola virus more quickly

The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time. Whilst the risks

#804 Progress towards an MVP to globally benchmark AI symptom assessments

“In the beginning, no one could really imagine how such complex systems like ‘AI symptom checkers’ could be benchmarked, but now this topic group is showing to be actually cracking this nut.”

#805 ProBioGen licenses GlymaxX® Technology to AbbVie

ProBioGen AG has signed a commercial license agreement with AbbVie for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC). The

#806 Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm,

#807 Open innovation challenge for Sustainable materials solutions

Rubbers & plastics for the automotive industry ABOUT THE CHALLENGE We are looking for sustainable material solutions based on rubber and plastics for fluid lines in automotive

#808 Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million over 3 Years for Development of Myelo001 as Treatment for Acute Radiation Syndrome

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a

#809 The start up accelerator for advanced materials

The Advanced Materials Competition (AdMaCom) is a fast-paced 2 week Accelerator Program for Startups in Advanced Materials.  AdMaCom focuses on: IP Strategy, Investment & funding

#810 Eckert & Ziegler to Start Development of Radioisotope Production Facility in Jintan, PR China

Berlin, 12 February 2021. Eckert & Ziegler (ISIN DE0005659700), a global specialist for radioactive medical and industrial applications based in Berlin, Germany, has signed an investment

#811 THE DANGEROUS DUAL ROLE OF THE IMMUNE SYSTEM IN COVID-19

Infection with the novel coronavirus SARS-CoV-2 follows a highly variable course: some of those infected do not even notice it, while others become so seriously ill that their lives are placed at

#812 First-in-human clinical study results

Cardio-microcurrent device for chronic heart failure: first-in-human clinical study Most devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a

#813 Targeted deep brain stimulation to treat obsessive-compulsive disorder

…harite.de/en/service/press_reports/artikel/detail/the_electrif…

#814 ProBioGen licenses GlymaxX® Technology to Sanofi

Enhancement of Target Cell Killing for Innovative Therapies ProBioGen AG has signed a commercial multi-product license agreement with Sanofi. Under such agreement, Sanofi will integrate ProBioGen’s

#815 Charité Dean Axel Pries to be new president of World Health Summit from 2021 on

Founder Detlev Ganten relinquishes office after 12 years Prof. Dr. Axel R. Pries, dean and member of the board of Charité - Universitätsmedizin Berlin, will be the new president of the World Health

#816 Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors. Glycotope GmbH, an oncology/immuno-oncology platform company built on world-leading glycobiology expertise, today

#817 Milestones to success: how to turn research into health

Translate! A symposium hosted by the BIH Center for Regenerative Therapies on January 25 and 26 The mission of the Berlin Institute of Health is medical translation, which involves transferring

#818 ​​​​​​​Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in USA

Eckert & Ziegler is proud to announce that it is expanding its production site in Wilmington just north of Boston, Massachusetts of a new production facility for the contract manufacturing of

#819 ProBioGen enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project

ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project. Earlier work confirmed already the versatility and benefit of

#820 Asher Biotherapeutics contracts ProBioGen to develop and manufacture their Lead Candidate

ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000

#821 Global Innovation Collaborative

A collaboration between Berlin, London, New York and Paris to leverage our collective innovation and speed our recovery from Covid-19 Who we are Berlin, London, New York and Paris have come

#822 Learnings from Covid-19 & Partnership Opportunities with Bayer G4A

Fr., 4. Juni · 17:00 MESZ Details Join one of our webinars to gain insights about this year’s partnership opportunities for digital health innovators with Bayer G4A! We will reflect on

#823 ProBioGen and Minapharm incorporate subsidiary

The company will enhance accessibility to medicines for Egypt, the Middle East and Africa while strengthening regional and local manufacturing capacities ProBioGen and Minapharm Pharmaceuticals

#824 Seed round oversubscribed: Bluu Biosciences secures €7 million – Europe's first cell-based fish biotech company takes off

…Berlin-based biotech Bluu Biosciences has closed its seed funding…

#825 Myelo Therapeutics Receives Additional NIAID Funding to Advance Development of Myelo001 for Acute Radiation Syndrome

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced today that the U.S. National

#826 Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm® (68Ge/68Ga Generator) and investigational product

#827 Eckert & Ziegler Takes over Brazilian Isotope Specialists - Strengthening their Presence in South America

Berlin, 2 August 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) acquired Ambientis Radioproteção, based in Sao Paulo, Brazil, effective July 31st, 2021 via its subsidiary Eckert &

#828 Nobelpharma signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®

ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to develop their lead vaccine. The signing of the

#829 Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet

#830 MedTech startup Smarterials Technology closes second seed financing round

MedTech startup Smarterials Technology GmbH has successfully closed its second round of financing. Led by High-Tech Gründerfonds (HTGF), pre-seed investors Think.Health Ventures and Emanet also

#831 Berliner Startup Stipendium – New call for a Sustainable City

You have an idea that needs to become reality? Your research could make this world a better place if turned into a product or service? Science & Startups and our network partners TU, HU, FU and

#832 Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR

… by the malignant proliferation of plasma cells in the…

#833 Eckert & Ziegler Acquires Property for Radiopharmaceutical Production Site in China

Berlin, 5 November 2021. Eckert & Ziegler AG (ISIN DE0005659700), a global specialist for isotope applications in medicine and industry has acquired an approximately 7,000 m² property with an

#834 Ada Health announces partnership with AXA OneHealth

Ada Health and AXA OneHealth bring digital healthcare solutions to Egypt Ada Health’s full range of medical AI solutions to be integrated in AXA OneHealth’s digital services, improving the

#835 Noxxon secures €17 million expansion of equity-linked facility with atlas to advance nox-a12 in glioblastoma and pancreatic cancer programs

• Substantial extension of financial runway visibility into December 2022 • Financing availability secured for initiation of NOX-A12 Phase 2/3 in Glioblastoma and Phase 2 in Pancreatic Cancer,

#836 ​​​​​​​Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

Berlin, 10 January 2022. Eckert & Ziegler Radiopharma GmbH (EZR), the radiopharmaceutical production arm of Eckert & Ziegler, has signed a joint venture and exclusive long-term supply

#837 German Chancellor delighted after company visit to KNAUER, calling the company a pearl

Dr. Angela Merkel visited laboratory instrument manufacturer KNAUER, that produces equipment for corona vaccine production. Berlin-Zehlendorf: German Chancellor Dr. Angela Merkel visited

#838 Insulin Directly Regulates the Circadian Clock in Adipose Tissue

Eating at the wrong time of day disrupts our circadian rhythm and increases the risk of obesity and type 2 diabetes. The team led by PD Dr. Olga Ramich of DIfE, Professor Achim Kramer and Professor

#839 Gates Foundation: commitment to global health

As one of the leading NGOs in the area of global health, the Bill & Melinda Gates Foundation has one of their Europe offices in Berlin. The capital values the foundation above all as one of the

#840 An indispensable pitstop for the gene copy machine

The enzyme complex that reads genes carries other factors “piggyback” along the DNA to their destination. The protein BRD4 is essential for this process: the factors dock onto the protein during a

#841 Charité develops a ‘Health Data Cloud‘ with EBRAINS to help shape the European Health Data Space

EBRAINS, the new digital research infrastructure developed by the EU-funded ‘Human Brain Project’, has been included in the 2021 Roadmap of the European Strategy Forum on Research Infrastructures

#842 Imvaq Therapeutics signs a Service and Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

Berlin, Germany and New York, USA, January 6, 2022: ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech

#843 The tricks of lymphomas

… As they describe in “Cell Reports”, this cancer induces…

#844 Food tech startup Perfeggt – The egg without chicken – raises 2.8 million USD

Plant-based egg alternative made in Germany closes first funding round with leading AgriFood investors from around the globe Plant-based egg alternative backed by leading international food and

#845 BIOTRONIK Patient App Facilitates Digital Patient Engagement

… have access to patient-reported symptoms. As a result,…

#846 Artificial intelligence in the healthcare sector: Lindera successfully closes financing round of six million euros

Lindera – one of the leading deep-tech companies in the field of computer vision – has successfully closed a Series A financing round. The Berlin-based health-tech company is receiving

#847 Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook

…d/ezag/investors-financial-reports/deutsch/euzj21e.pdf About…

#848 ​​​​​​​Eckert & Ziegler Acquires Argentinian SPECT Specialist

Berlin, 3 January 2022. Eckert & Ziegler has acquired 100% of the shares of Argentinian nuclear medicine specialist Tecnonuclear S. A., a manufacturer of Technetium-99 generators and a

#849 German National Cohort data accessible for research

The NAKO Health Study collected data from 205,000 participants in its initial surveys. The German-speaking scientific community can now use the TransferHub to evaluate the data in their own studies.

#850 Charité researchers identify key signaling pathway involved in Lymphoma tumor formation

… factors such as their lifespan and location within the…

#851 Combination is key – new treatments for lung and colon cancer?

… to inhibit tumor cell proliferation and thus to overcome…

#852 Apply for the Creative Destruction Lab (CDL) Program

CDL-Berlin is located in Germany’s most vibrant startup ecosystem and hosted by ESMT Berlin, Germany’s #1 business school. By being deeply embedded in Germany’s deep tech economy, ESMT holds close

#853 Max Planck Institute for Molecular Genetics (MPIMG) decoded epigenetic mechanisms for parent-specific genetic activation

Epigenetic mechanisms for parent-specific genetic activation decoded Hereditary diseases as well as cancers and cardiovascular diseases may be associated with a phenomenon known as genomic

#854 ProBioGen signs a commercial license agreement with AstraZeneca providing their GlymaxX®

ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology. Under this license agreement, Innovent receives

#855 Corona: New Insights into Antibody Response against Viral Variants

…harite.de/en/service/press_reports/artikel/detail/corona_new_i…

#856 Researchers from Charité and MDC discover reasons for treatment resistance of multiple myeloma

… “The cancer cells' proliferation potential may also be…

#857 Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH Berlin, Germany, February 1, 2022 – Glycotope GmbH, a biotechnology company developing antibodies against proteins

#858 Female Founders Award 2023 | Apply or Nominate Now!

On April 26, 2023, the American Chamber of Commerce in Germany (AmCham Germany) will present its Female Founders Award for the fourth time in Berlin. Two female (co-) founders will receive the

#859 Startup Pitch Competition on April 28 - SelectUSA Investment Summit

Are you a startup or early-stage tech company from Germany interested in expanding into the United States?  If so, then you are invited to apply to participate in the U.S Embassy’s Second Annual

#860 Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing

#861 Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market

Berlin, 22 March 2022. Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for

#862 Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

Berlin, 23 March 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert &

#863 Free service for medical AI researchers: AskPaper.ai

The Hippo AI Foundation is proud to announce the launch of AskPaper.ai, a free service designed to give time back to medical AI researchers. AskPaper.ai is a one of its kind tool that allows

#864 Microbial cooperation as one of the causes of drug tolerance in fungal infections discovered by Charité researchers

…harite.de/en/service/press_reports/artikel/detail/fungal_infec…

#865 Insertable Cardiac Monitors (ICM) and Remote Monitoring May Improve Outcomes for Post-Myocardial Infarction Patients, Study Demonstrates

Presentation at ACC.22 shows early treatment of high-risk NSTEMI patients guided by continuous arrhythmia monitoring with ICMs may reduce major adverse cardiac events (MACE) Final results from

#866 Combination of wearable data and digital questionnaires: FeMFit study by Data4Life opens up new paths in research on female health

… company Data4Life is expanding its research…

#867 PEI Regulatory Approval Received for Government Funded (€ 7.4 Million) Clinical Trial Investigating Adrenomed’s Adrecizumab in Treating Endothelial Barrier Dysfunction in Hospitalized COVID-19 Patients

Adrecizumab selected to receive funding from two COVID-19 drug development programs of the German Federal Ministry of Education and Research (BMBF) By restoring vascular integrity, Adrecizumab

#868 Charité researchers identified a large number of specific genes which play a key role in the onset and development of schizophrenia

…harite.de/en/service/press_reports/artikel/detail/towards_a_be…

#869 Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

… 5.9 %. The number of unreported cases is even higher due…

#870 Charité and MDC discover how a bacterial infection causes tissue changes in gastric inflammation

… stimulating the proliferation of nearby stem cells.…

#871 Charité researchers secure two new ERC Consolidator Grants

… throughout its…

#872 Dr. Lutz Hilbrich, Chief Executive Officer at ProBioGen (and the subsidiary MiGenTra) and Andrea Hauptmann, Chief Financial Officer at ProBioGen (and the subsidiary MiGenTra)

ProBioGen was founded in Berlin in 1994, and has been part of the Egyptian Minapharm Group since 2010. The biotech company and its subsidiary MiGenTra operate around the globe and have years of

#873 Memorandum signed on establishing a center of gene and cell therapy

The state of Berlin, Bayer, and Charité are planning a health care lighthouse project in the Mitte borough Governing Mayor of Berlin Franziska Giffey, together with Stefan Oelrich, Member of

#874 Bluu Seafood, Europe's pioneer in cultivated fish. kick off strategic partnership with CellX, China's pioneer in cultivated meat

… Seafood (formerly Bluu Biosciences) and CellX, two pioneers…

#875 LABORATORY EQUIPMENT SPECIALIST KNAUER WANTED TO HELP SAVE THE WORLD AND NOW RECEIVED GERMAN INNOVATION AWARD

… The jury, it was reported, had a hard time…

#876 Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

Berlin, 12 April 2023 – Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA)

#877 Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe

MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy Europe. The certificate of appointment was

#878 Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting

Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting Berlin, Germany, 17 April, 2023 – Glycotope GmbH, a biotechnology company

#879 BIH researchers discovered a mechanism keeps stem cells intact for a lifetime

…-cells-stay-intact-for-a-lifetime

#880 Interview | Prof. Dr. Emmanuelle Charpentier, Max Planck Unit for the Science of Pathogens (MPUSP)

"Basic research is the basis for innovation" Brain City Berlin https://braincity.berlin/en/stories/story/grundlagenforschung-ist-die-basis-fuer-innovationen For her groundbreaking work

#881 MDC researchers have created protein maps of tumors that aim at finding therapies for resistant tumors

… a German-Danish team now reports in “Nature Biotechnology”.…

#882 MDC researcher has described how sensory neurons near the central canal in the spinal cord help regulate motor functions

… of the Institut de Neurosciences de la Timone at the…

#883 Using an app to combat skin conditions: Nia Health receives millions in funding

The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading

#884 Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of

#885 LegoChem Biosciences and Glycotope announce research collaboration and license agreement for an antibody for use as antibody drug conjugate

… 2022) – LegoChem Biosciences Inc. (LCB)…

#886 How to find marker genes in cell clusters

New method facilitates identification of cell-type specific genes in single-cell data The thousands of cells in a biological sample are all different and can be analyzed individually, cell by cell.

#887 MDC research team discovered how zebrafish can regenerate heart tissue

… state, as the team reports in “Nature Genetics”.

#888 MDC researchers discovered how molecular boundaries across the genome work

The way the genome is folded regulates gene activation, so it can’t be left to chance. Molecular boundaries across the genome keep things in order. A team led by MDC researcher Darío Lupiáñez has

#889 Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

BERLIN, GERMANY, August 04, 2022 – Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) and member of a pan-European

#890 Bayer proudly sponsors BIO-EUROPES Startup-Spotlight – Apply to Pitch!

At Bayer, we’re passionate about enabling and supporting great ideas in healthcare – We are proud to sponsor Bio Europe’s Startup Spotlight (November 6–8, 2023 in Munich, Germany). @ Cell

#891 International consortium including MDC brings together 7,200 segments of the human genome that are virtually unexplored

… the human heart and reported on them in “Cell” in…
Show more items